ERLEADA® + ADT demonstrates a consistent, acceptable safety profile[2]
ERLEADA® is indicated in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), in combination with ADT.[1]
Medical castration with gonadotropin-releasing hormone analogue (GnRHa) should be continued during ERLEADA® treatment in patients who have not undergone surgical castration.[1]
ERLEADA® is a practical and convenient treatment for you and your patients[1]
.jpg?width=1920&height=1920&format=webp&quality=50 "Calculator icon"){kind=icon}
240 mg once-daily dosing
.jpg?width=1920&height=1920&format=webp&quality=50 "Food icon"){kind=icon}
Can be taken with or without fooda
.jpg?width=1920&height=1920&format=webp&quality=50 "Home icon"){kind=icon}
Convenient oral treatment at homeb
aTablets should be swallowed whole.[1]
bNo additional laboratory monitoring requirements beyond routine assessments for AEs.[1]
You can delay the threat of castration resistance in mHSPC with ERLEADA® + ADT – the practical, once-daily, oral treatment[1][2]
Click below to find out more about the clinical benefits with ERLEADA® + ADT:
Treat early with ERLEADA® + ADT to delay progression and extend life for your mHSPC patients vs. placebo + ADT[2]
Extend life across a broad range of mHSPC patients with ERLEADA® + ADT[2]
Push back on progression and maintain QoL in mHSPC[2]
Abbreviations
ADT, androgen deprivation therapy. AE, adverse event. mHSPC, metastatic hormone-sensitive prostate cancer.
Titular da Autorização de Introdução no Mercado: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Bélgica.
Para mais informações deverá contactar o Representante do Titular da Autorização de Introdução no Mercado: Janssen-Cilag Farmacêutica, Lda.
Medicamento de receita médica restrita, de utilização reservada a certos meios especializados.
Antes de prescrever consulte o RCM completo.
RCM de Erleada®, veja aqui
